← Back to Screener
Silo Pharma, Inc. Common Stock (SILO)
Price$0.67
Favorite Metrics
Price vs S&P 500 (26W)-17.11%
Price vs S&P 500 (4W)33.56%
Market Capitalization$8.38M
All Metrics
Book Value / Share (Quarterly)$0.48
P/TBV (Annual)0.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)0.99%
Cash Flow / Share (Quarterly)$-0.47
Price vs S&P 500 (YTD)47.33%
Gross Margin (TTM)65.24%
Net Profit Margin (TTM)-7039.36%
EPS (TTM)$-0.93
10-Day Avg Trading Volume19.75M
EPS Excl Extra (TTM)$-0.93
Revenue Growth (5Y)12.51%
EPS (Annual)$-1.19
ROI (Annual)-87.26%
Gross Margin (Annual)91.90%
Net Profit Margin (5Y Avg)-2752.95%
Cash / Share (Quarterly)$0.56
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-59.27%
Revenue Growth TTM (YoY)0.00%
EBITD / Share (TTM)$-0.86
ROE (5Y Avg)-75.89%
Operating Margin (TTM)-7359.23%
Cash Flow / Share (Annual)$-0.85
P/B Ratio1.67x
P/B Ratio (Quarterly)1.44x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)61.84x
Net Interest Coverage (TTM)-9.57x
ROA (TTM)-77.07%
EPS Incl Extra (Annual)$-1.19
Current Ratio (Annual)4.29x
Quick Ratio (Quarterly)8.38x
3-Month Avg Trading Volume2.89M
52-Week Price Return-50.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.46
P/S Ratio (Annual)116.19x
Asset Turnover (Annual)0.01x
52-Week High$1.19
Operating Margin (5Y Avg)-4656.98%
EPS Excl Extra (Annual)$-1.19
Tangible BV CAGR (5Y)45.19%
26-Week Price Return-8.36%
Quick Ratio (Annual)4.28x
13-Week Price Return31.48%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.70x
Enterprise Value$4.46
Revenue / Share Growth (5Y)-25.45%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)7.36%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.67x
Pretax Margin (Annual)-6092.76%
Cash / Share (Annual)$1.58
3-Month Return Std Dev141.61%
Gross Margin (5Y Avg)81.76%
Net Income / Employee (TTM)$-2
ROE (Last FY)-87.26%
Net Interest Coverage (Annual)-9.83x
EPS Basic Excl Extra (Annual)$-1.19
P/FCF (TTM)17.45x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.93
Receivables Turnover (Annual)2.18x
ROI (TTM)-107.04%
P/S Ratio (TTM)116.16x
Pretax Margin (5Y Avg)-2653.64%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$1.07
Price vs S&P 500 (52W)-85.09%
Year-to-Date Return51.47%
5-Day Price Return19.52%
EPS Normalized (Annual)$-1.19
ROA (5Y Avg)-63.21%
Net Profit Margin (Annual)-6092.76%
Month-to-Date Return43.17%
EBITD / Share (Annual)$-1.28
Operating Margin (Annual)-6526.63%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-75.16%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.93
P/TBV (Quarterly)1.51x
P/B Ratio (Annual)0.79x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-7039.36%
Book Value / Share (Annual)$1.12
Price vs S&P 500 (13W)28.61%
Beta-35.01x
P/FCF (Annual)31.03x
Revenue / Share (TTM)$0.01
ROE (TTM)-107.04%
52-Week Low$0.22
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SILOSilo Pharma, Inc. Common Stock | 116.16x | 0.00% | 65.24% | — | $0.67 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
SILO Pharma is a developmental stage biopharmaceutical company developing treatments for underserved psychiatric, pain, and neurological disorders using novel drug formulations and delivery systems. The company combines traditional and psychedelic-based therapeutic approaches, with its lead candidate, SPC-15, an intranasal treatment for PTSD and stress-induced anxiety.